Advances in molecular biology have given us the tools to dissect the mechanisms which control the circulation of leucocytes. In particular, a sequence of intermolecular adhesive interactions has been described which underlies leucocyte attachment to the vessel wall, and the factors which promote and limit these interactions have begun to be appreciated. These discoveries have led to a rekindling of interest in the inflammatory response arising from extravasation of neutrophils and to a growing understanding of the basis of lymphocyte recirculation and targeting to specific organs [9, 72, 97] . Much work has been based, of necessity, on in vitro model systems, but animal studies and intravital techniques have enabled the molecular concepts to be tested, so that there is growing confidence that they are indeed the basis of physiological and pathological processes. Multiple organ failure (MOF) is attended by disturbance of tissue perfusion and degradative damage associated with an extreme inflammatory response, which may arise, in part at least, from a loss of the normal mechanisms controlling leucocyte circulation and migration into tissue [109] . It is thus our aim to review the circulatory and adhesive behaviour of leucocytes (especially neutrophilic granulocytes or neutrophils), along with its molecular basis and control mechanisms, and to evaluate the evidence that disruption of the normal physiological processes contributes to pathologies such as MOF.
Circulation of leucocytes

LIFESPAN, CIRCULATION AND RHEOLOGY
Although a large proportion of mature leucocytes are circulating at any given time, their physiological function is not carried out in the vascular compartment. Thus, neutrophils circulate for about 7-10 h on average before migrating into tissue as part of an inflammatory response where they phagocytose and destroy foreign bodies and necrotic tissue. The neutrophils found in the systemic blood represent only about 50 % of the circulating pool, so that there is a marginated population travelling slowly through the lungs and microcirculation which can be mobilized rapidly, for example by exercise or catecholamines [12] . Monocytes circulate for a similar period, but then become resident in tissues as macrophages for a period up to months, acting as a potent source of mediators such as cytokines, and forming an active part of the phagocytic reticuloendothelial system in the spleen, liver and bone marrow. Lymphocytes have a more complex pattern of behaviour, because they are the only leucocytes that return to the blood via the lymphatic system after migration into tissue (i.e. recirculation; see Ager [19] for review). The tissue to which they migrate depends on their subtype and activation status (see below).
The transformation from a circulating leucocyte to a non-circulating or migrated leucocyte depends on changes in the cellular rheological properties of resistance to mechanical deformation and adhesiveness. Successful passage through the microcirculation is dependent on the deformability of the leucocytes (because capillary diameter is often less than the cell dimensions) and on maintenance of a non-adhesive response to the endothelium. As is made evident below, the endothelial cells lining the microvessels, particularly on the venous side, are not passive partners in the potential adhesive interaction. At this stage it is sufficient to realize that it is disturbance in the balance of physical forces which determines whether or not a cell becomes immobilized in the microcirculation (i.e. circulatory driving force vs resistance to deformation or vs adhesive interaction). In the "physiological" response, controlled adhesive interactions enable leucocytes to attach to the vessel wall, and modulation of cellular mechanical properties allows locomotion and migration into tissue. However, uncontrolled changes in adhesive or cellular mechanical properties or in circulatory forces may lead to trapping in microvessels that could be "pathological".
MECHANICAL FAILURE TO CIRCULATE-A CONTRIBUTOR TO CIRCULATORY DISORDER?
Outside of severely hyperleucotic leukaemias, it is generally considered that leucocytes do not contribute to the bulk flow resistance of the blood in large vessels. However, although outnumbered by red cells by about 700 : 1, leucocytes can contribute to the resistance to flow and distribution of flow in microvessels [38] . This is because the intrinsic resistance to flow into a small capillary is about 1000-fold greater for a leucocyte than a red cell [28] . Thus, it has been recognized from intravital observations, including those made in humans, that even normal leucocytes travel very slowly into capillaries, have the ability to hold up "trains" of red cells and can cause stop-go flow in individual capillaries [13, 14] . This seems to apply to each class of leucocyte, although all evidently negotiate the microcirculation successfully in the steady state. Problems may arise, however, if perfusion pressure is reduced or if neutrophils, in particular, become activated.
Studies in animal models show that reduction of perfusion pressure, induced artificially or after shock, leads to plugging of capillaries by leucocytes and increase in flow resistance [13] . Moreover, the return of driving pressure to normal does not seem to enable perfusion to be completely recovered. A similar series of events follows arterial ligation, for instance in animal models of myocardial infarction [33] . It appears that initial trapping of "normal" leucocytes may be mechanical, but that a process of activation ensues for neutrophils, probably prompted by mediators released in the affected tissue (e.g. activated complement, eicosanoids or endothelial-derived factors such as interleukin 8 (IL-8) or platelet-activating factor (PAF)). Activation causes rapid rigidification of neutrophils because of the formation of actin polymer in the cytoplasm [34] and also increases their adhesive potential (see below). Actin polymerization is the motor for migration of leucocytes into tissue, but if stimulated at an inappropriate time it will inhibit their circulation. Adhesion, as well as enabling extravascular migration, may also promote vascular occlusion. Such activation-induced changes in mechanical and adhesive properties will tend to stop cells from being dislodged after return of perfusion pressure. Not only this, but reperfusion brings new leucocytes to the tissue, which are in turn activated by mediators and change their mechanical and adhesive properties [85] . Thus there is the potential for a vicious cycle of increasing vascular blockage followed by tissue damage arising from the lytic enzymes and oxidants known to be released by activated neutrophils ( fig. 1 ) [64, 106] .
That such a process follows ischaemic and inflammatory events has been demonstrated in animal models [13, 85, 107] and is evidenced in humans by findings of systemic activation of neutrophils and changes in their mechanical properties [62, 64, 65] . Thus, it may be that circulatory obstruction occurs locally in an "insulted" tissue but also becomes disseminated because of release of activated cells (e.g. those which do not respond rapidly enough to be trapped locally), stimulatory mediators, or both. Such mediators may act on circulating neutrophils and also on remote endothelial cells to change their adhesive properties (see below). The lung may act as a filter of activated cells because of its low perfusion pressure and peculiar microvascular structure, where cells must pass through a series of capillary segments without shunting. The basis of trapping might be mechanical, adhesive, or both, although animal studies suggest that mechanical changes alone can be sufficient [112] . Other organs, such as the spleen, liver and kidney may also be susceptible because of structural features which promote trapping of rigid cells. The mechanical factors likely to influence the sites of microvascular entrapment of leucocytes are summarized in figure 2.
CONSTRAINTS PLACED ON ADHESION BY CIRCULATION
Another important implication of circulatory dynamics and forces is that they impose constraints on the adhesive processes underlying leucocyteendothelial interaction [45] . Leucocytes appear to adhere mainly in post-capillary venules where their velocities are relatively low but still of the order of hundreds of m s
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. Given the dimensions of the interacting cells and of the adhesion molecules on their surface, it is clear that individual molecular interactions have to be rapid to make the chance of capturing a cell finite. It has thus been realized that it is the kinetics of intermolecular adhesive interactions that are important (i.e. the "on-rates" relative to the flow rate, rather than the equilibrium affinity constants) in limiting cell capture [108] . Once adhesive bonds have formed, then they are put under stress by the fluid drag acting on the now stationary cell. These forces tend to break the bonds, and so capture might be followed by detachment, unless stabilizing bonds are formed rapidly. Alternatively, cells may roll slowly along the surface after capture because they are able to form new bonds at the front while bonds "peel" at the rear of the cell [104] . In addition, migration after stabilization implies that cells can unstick and re-stick themselves as they move, with flow forces acting on them continually until they have exited the vessel lumen. It would seem unlikely a priori that a single type of receptor-ligand interaction could have the necessary physical characteristics to support all stages of such a process in a controlled manner. Indeed molecular specialization appears to have been evolved in order to overcome this problem, and is described in the next section, along with our current understanding of how leucocyte adhesion to endothelium is achieved. 
Leucocyte migration and recirculation
Leucocytes migrate extensively throughout the body to maintain immune surveillance and to mount rapid inflammatory responses to invading pathogens [6] . Different leucocytes have particular patterns of migration that are suited to their functional capacities. For instance, as mentioned above, neutrophils are a population of relatively simple effector cells that form an early response to infection or injury. They are rapidly recruited in large numbers to sites of inflammation where they are activated to release their intracellular contents. This activation is provided by general mechanisms and is not dependent upon the precise structure of the offending antigen, i.e. it is antigen-independent. Neutrophils do not recirculate and once they have entered tissue they either die by activation and release of cytoplasmic contents or they are removed by phagocytic macrophages.
T-lymphocytes, on the other hand, are a highly sophisticated population of cells, that are activated by specific antigens to which they have been programmed to respond. In most circumstances Tlymphocytes are recruited later and more selectively than neutrophils to diverse sites of inflammation. In contradistinction to neutrophils, T-cells have the ability to return to the circulation via the lymphatics. This permits them to recirculate through normal tissue and provide ongoing immune surveillance [72] . Their ability to respond to specific foreign peptides allows them to mount a highly selective response to invading foreign antigens [20, 99] . Naive T-cells (those that have not been exposed to antigen) recirculate almost entirely through lymphoid tissue where they are most likely to encounter their specific antigen in the specialized environment of the lymph node where optimal antigen presentation and activation can occur. However, after exposure to antigen in lymphoid tissue the naive T-cell returns to the resting state as a memory cell, primed to respond rapidly to a second encounter with antigen. In order to enhance its chances of re-encountering its specific antigen the memory T-cell recirculates preferentially through the tissue in which it was originally exposed to antigen [6, 72] .
These subtle patterns of recirculation can be overcome in inflammation where release of proinflammatory factors results in the recruitment of a wider range of cell types. The composition of an inflammatory infiltrate will depend upon the nature of the pathogenic stimulus; for instance, the infiltrate of an allergic reaction may contain large numbers of eosinophils whereas T-cells and macrophages predominate in graft rejection and neutrophils at sites of acute bacterial sepsis. Furthermore, the inflammatory infiltrate changes over time, for instance an initial type I hypersensitivity reaction will provoke an influx of mast cells and eosinophils which will be Figure 2 Factors influencing the site of mechanical trapping of neutrophils in tissue. Cellular resistance to flow is greatly dependent on vessel diameter [25] , so that organs with narrow capillaries or sinusoidal structure, and with vascular architecture lacking shunts will be likely to filter cells, especially if the perfusion pressure is low (e.g. in the lungs). The same factors apply for rigidified neutrophils after activation, but if the mechanical response after activation is rapid, cells may be trapped in the tissue where the stimulus originated, while a slow response will lead to dissemination of the cells in the circulation. Figure 3 Mechanical factors affecting circulation of leucocytes passing from arterioles to capillaries to venules. Cells may need to undergo marked deformation and elongation to pass through capillaries (1) , and may be unsuccessful if the perfusion pressure is reduced (2) or if they are activated by systemic (3) or local stimuli (4) . Cells may adhere to venules if they can form bonds rapidly enough compared with flow rate (5) and if adhesive bonds can withstand shear forces (6) . Cells failing to attach when stimulated (7) and released into the blood may be systemically active.
Figure 4
Adhesion to endothelium and subsequent transendothelial migration is regulated by a cascade of interactions between the leucocyte and the endothelium. A: The first step (primary adhesion) involves tethering of the leucocyte to the endothelium by comparatively weak and transient bonds provided by selectins on either the endothelium (e.g. E-selectin) or the leucocyte (L-selectin) that bind to carbohydrate receptors on the opposing cell. This allows the leucocyte to come into contact with pro-adhesive factors (typically chemokines) that are immobilized in the endothelial glycocalyx and provide a trigger for integrin activation and strong secondary adhesion. This strong adhesion is mediated by leucocyte integrins binding to members of the immunoglobulin superfamily on the vessel wall. The final step in the cascade is transendothelial migration which is promoted by chemotactic factors such as chemokines. Chemokines are produced by the endothelium itself or by inflammatory cells in the subendothelial tissues. B: Diagrammatic representation of the major molecules involved in the adhesion cascade between leucocytes and endothelium. The tethering step is provided by selectins and allows chemokines immobilized on proteoglycan in the endothelial glycocalyx to engage specific receptors on the leucocyte. This results in conformational activation of leucocyte integrins permitting their adhesion to endothelial receptors of the immunoglobulin family. In addition, chemokines promote cytoskeletal changes and the induction of motility.
followed later by macrophages and T-cells if the lesion becomes chronic. Such complex inflammatory responses must be mediated by specific mechanisms capable of recruiting particular subsets of leucocytes dependent on the inflammatory stimulus [97] .
LEUCOCYTE RECRUITMENT TO TISSUE IS REGULATED BY SEQUENTIAL ADHESIVE INTERACTIONS WITH
ENDOTHELIUM
Clearly leucocyte migration must be carefully regulated both to maintain immune surveillance and to enable different inflammatory responses to invading stimuli to be established. For instance, inappropriate recruitment of granulocytes to normal tissue could result in tissue damage from release of proteolytic enzymes and reactive oxygen intermediates whereas a failure of T-cells to migrate through normal tissue would impair immune surveillance. The fact that leucocytes must first recognize and then bind to the endothelium before they can migrate into tissue provides a powerful mechanism for regulating their recruitment. This adhesive interaction with endothelium is a dynamic process involving the activation both of the endothelium and the leucocyte [6, 97] . Leucocyte recruitment occurs when a cascade of sequential interactions between the leucocyte and the endothelium results in the flowing leucocyte coming into contact with the endothelium, stopping at the vessel surface and then migrating into tissue in a regulated manner.
The first step in this process is primary adhesion, or "tethering" which slows the flowing cell by inducing it to roll or bump along the endothelium. After this initial encounter cells may either disengage and be carried away by the flow or, in the presence of the correct triggering factor, undergo secondary adhesion during which binding to the endothelium is stabilized and the leucocyte changes shape, becomes flattened and strongly adherent to the vessel wall. Over the next few minutes the cell migrates between the endothelial cells into tissue, a process termed diapedesis.
Thus, there are four requirements for leucocyte recruitment: (1) tethering or primary adhesion, (2) triggering of strong adhesion, (3) strong adhesion, and (4) transendothelial migration into tissue.
MULTIPLE ADHESION MOLECULES ARE INVOLVED IN LEUCOCYTE BINDING TO ENDOTHELIUM
A number of structurally diverse adhesion molecules, are involved in this adhesion cascade [6, 21] ( fig. 4 and table 1 ). The expression of these molecules is regulated with differentiation and activation both of the endothelium and the leucocyte and is therefore a dynamic process in which both cell types play an active role [97] .
Selectins mediate primary, tethering adhesion
A family of lectin-like adhesion molecules called selectins support leucocyte rolling under flow conditions when they bind to carbohydrate receptors [51] . One of these molecules, L-selectin, is widely expressed on leucocytes. Different leucocytes express distinct forms of L-selectin which can undergo extensive post-translational modification by glycosylation thereby altering receptor specificity. Thus, L-selectin expressed by naive T-cells binds receptors on lymph node endothelium and is involved in the homing of naive cells to lymphoid tissue [73] , whereas L-selectin on neutrophils does not mediate binding to lymph node endothelium but instead supports binding to inflamed endothelium.
Two other selectins, E-selectin (CD62E) and Pselectin (CD62P) are synthesized and expressed by endothelial cells after cytokine activation with, for example, IL-1 or TNF␣. E-selectin binds to poorly defined oligosaccharide receptors on neutrophils and monocytes and to a subset of CD4; memory T-cells which express a receptor called the cutaneous lymphocyte antigen [92] . P-selectin is also expressed by activated endothelium and by platelets. P-selectin can be rapidly mobilized from cytoplasmic granules (Weibel-Pallade bodies) to the endothelial cell surface on activation. Although most interest has focused on the ability of P-selectin to mediate neutrophil rolling a subset of T-cells can also bind to P-selectin in vitro suggesting a possible role for this molecule in T-cell endothelial interactions [31] . Thus, each selectin recognizes specific carbohydrate sequences and different combinations of receptor and ligand will promote the recruitment of particular leucocyte subsets.
Three properties make selectins ideal mediators of primary adhesion/tethering: (i) Structure and localization. E-selectin and Pselectin are long molecules that extend out of the surrounding endothelial glycocalyx to make contact with passing leucocytes and L-selectin is concentrated on the tips of leucocyte microvilli where it can best make contact with the endothelial surface.
(ii) Selectins mediate activation-independent adhesion. Leucocytes do not require prior activation to interact with selectins. This is important for an initial adhesive interaction which will take place with a circulating leucocyte that has not yet come into contact with local activating factors. It has recently been reported that other molecules can mediate primary adhesion of lymphocytes [72] . For example, the integrin ligand VCAM-1 can mediate both primary (tethering) and secondary (strong) adhesion [44] . This may be particularly important in low-flow systems such as the lung, liver and spleen. Furthermore, in these systems it is possible that strong, integrin-mediated adhesion can take place without prior tethering.
Triggering of integrin-mediated adhesion by secreted factors
Strong, secondary adhesion to endothelium is mediated by leucocyte adhesion molecules of the integrin family. A characteristic property of integrins is their requirement for conformational activation before optimal ligand binding can occur [42] . Thus, a triggering step is required in the cascade during which integrins are functionally activated to bind to an appropriate endothelial counter-receptor [6] .
Trigger factors for leucocytes fall into two broad categories: (i) cell surface molecules, and (ii) cytokines and secreted factors. The former include Lselectin which, in addition to mediating tethering, can also transmit activating signals to leucocyte integrins when engaged by an appropriate receptor [93] and CD31, an adhesion molecule of the immunoglobulin superfamily that is widely expressed on endothelium and on a restricted subset of T-cells. Engagement of CD31 on these T-cells leads to a conformational change in the T-cell integrins LFA-1 and VLA-4 resulting in activation of binding to the endothelial ligands ICAM-1 and VCAM-1 [102] . Despite the above observations it is likely that the most important adhesion triggers are cytokines and secreted factors.
Pro-adhesive factors for neutrophils and monocytes.
It has been known for many years that a diverse group of soluble factors can act as chemoattractants for neutrophils and monocytes (table 2). These include bacterial-derived proteins such as the formyl peptides of which f-met-leu-phe (fMLP) is the best known, C5a, a complement complement, leukotriene B4, an eicosanoid, and platelet-activating factor (PAF), a product of phosphatidyl choline metabolism [97] . In addition, neuropeptides such as the endorphins have recently been shown to act as neutrophil chemoattractants [114] . As well as promoting chemotaxis many of these factors also activate leucocyte adhesion. Thus, they may play a dual role both as trigger factors and chemotactic factors, thereby promoting transendothelial migration into tissue.
By their nature one would expect the above factors to be released at sites of bacterial invasion or tissue injury. Consistent with this, their actions are largely restricted to cells of the myelomonocytic lineage which are rapidly recruited during acute inflammation. They do not have strong actions on lymphocytes and cannot, therefore, provide all the necessary signals to explain the specificity of leucocyte subset recruitment. The discovery of the chemokine family of chemotactic cytokines has provided the extra options which allow the paradigm to be extended to other leucocytes, notably lymphocytes [24, 97] .
The role of chemokines in leucocyte subset recruitment.
Chemokines are a family of structurally distinct cytokines, that are chemotactic and proadhesive for leucocyte subsets [52, 67, 81] . There are over 30 Table 2 Examples of different soluble factors that can trigger leucocyte chemotaxis. The growth factors described here are also cytokines in that they act on and between cells of the immune system; they have been included in a separate category here because, owing to their potent growth regulatory effects on other cell types, they are more commonly perceived as growth regulators rather than as immune regulators. Likewise, the term cytokines refers to the classic cytokines and excludes chemokines which are shown separately Table 3 Structural chemokine families. The C-C chemokines and the non-ELR subfamily of the C-X-C chemokines act predominantly on monocytes, lymphocytes and eosinophilis. The ELR C-X-C chemokines act on neutrophils and lymphotactin acts only on lymphocytes (for more details see text and ref. [15] known human chemokines all of which have a characteristic structure and share sequence homology [15] . They can be divided into three subfamilies based on their structure (see table 3 ). ␣-and ␤-chemokines have two disulphide bonds between a total of four cysteine residues whereas the C chemokines have only two cysteines. The ␣-chemokines, also known as C-X-C chemokines, are distinguished from ␤-chemokines or C-C chemokines because the first two cysteine residues from the Nterminal are separated by an intervening amino acid (hence C-X-C) whereas in the ␤-chemokines they are adjacent (C-C). These structural distinctions are important since they confer on chemokines the ability to act on particular leucocyte subsets (table 4) . Thus, most of the C-X-C chemokines which include IL-8 and gro/MGSA act predominantly on neutrophils whereas the C-C chemokines (RANTES, MCP-1) act on lymphocytes, monocytes and eosinophils; lymphotactin, the only C-family chemokine that has been functionally characterized so far acts solely on lymphocytes [48] . Some chemokines, i.e. IL-8 and MCP-1, are widely expressed in cells including platelets, leucocytes, endothelium and epithelium, whereas others have a more restricted distribution. Chemokines are expressed a low concentrations in resting cells but are rapidly upregulated on activation when chemokine mRNA can comprise up to 1 % of total cellular mRNA. The factors that activate cells to secrete chemokines vary depending on cell type, site and chemokine and include pro-inflammatory cytokines such as IL-1, TNF␣, gIFN, the bacterial cell wall product lipopolysaccharide and chemical mitogens such as phorbol esters.
All of the chemokines so far isolated bind to a family of G-protein-linked, transmembrane spanning receptors [61] . This family also includes the receptors for fMLP, C5a and LTB4. There are many chemokine receptors with differing ligand specificities.
They can be broadly and conveniently categorized into:
(i) specific receptors that only bind a particular chemokine: for example the IL-8RA receptor only binds IL-8;
(ii) receptors with restricted specificity such as the C-C chemokine receptor CKR-1 which binds most of the C-C chemokines but does not bind C-X-C chemokines and the IL-8 receptor RB which binds C-X-C but not C-C chemokines; (iii) promiscuous receptors such as the Duffy blood group antigen which is expressed on red blood cells and endothelium and binds all known chemokines.
Engagement of leucocyte chemokine receptors by ligand results in calcium mobilization, phosphokinase C (PKC) activation and cytoskeletal rearrangement within the cell. The functional consequences of this include enhanced migration and conformational activation of cell surface integrins to facilitate binding to ligand. Thus, IL-8 activates ␤2 integrin-dependent adhesion of neutrophils whereas macrophage inflammatory protein-1␤ (MIP-1␤), the first cytokine reported to trigger T-cell adhesion, activates the T-cell ␤1 integrin VLA-4 to bind to its endothelial counter-receptor VCAM-1 [100] . Since then several other chemokines have been shown to have such an effect; these include MIP-1␣, macrophage chemotactic protein-1 (MCP-1), RANTES and interferon-inducible protein-10 (IP-10) [103] .
Why can so many diverse cytokines trigger leucocyte adhesion to endothelium? There are two possible explanations: first, that this function is so crucial to host survival that several mechanisms have evolved resulting in a degree of redundancy. This possibility is being investigated in animal models using antibodies to neutralize particular chemokines and then testing the ability of the animal to respond to an inflammatory stimulus. Recently, mice have been developed in which the gene for a particular chemokine has been deleted. Such knock-out mice will provide valuable insights into the role of individual chemokines. The second possibility is that specificity within the chemokine family is tightly regulated and requires the existence of multiple chemokines to provide the required options. There is some evidence for this and it seems likely that specificity acts at several levels, for instance:
(i) Specificity for leucocyte subsets. If particular chemokines act on specific subsets of leucocytes multiple chemokines will be required to account for (iii) Differences are response to activating stimuli. Different chemokines are induced by particular proinflammatory cytokines. For example, the secretion of C-C chemokines such as MCP-1 is enhanced by ␥IFN whereas the secretion of most C-X-C chemokines such as IL-8 is inhibited.
There is evidence that all of these factors are important. However, there is overlap in the actions of most of the chemokines and the specificity of leucocyte recruitment is almost certainly regulated by the combined effects of all the elements in the adhesion cascade rather than by a highly specific chemokine (table 5) .
Pro-adhesive factors act as immobilized ligands.
In order to trigger adhesion and transendothelial migration effectively, pro-adhesive factors must be available at the vessel wall where they can interact with circulating leucocytes. Immunohistochemical studies have demonstrated chemokine staining on the vessel lumen and the mechanism of their retention in the endothelium has recently been elucidated (fig. 4) . Chemokines have glycosaminoglycan binding motifs that allow them to bind proteoglycans in the endothelial glycocalyx and thereby be retained at relevant sites [79, 100, 101 ]. An extra layer of complexity is provided by recent reports showing differences in the affinity of chemokines for particular proteoglycans. Since endothelial proteoglycans vary between different sites and can be altered in inflammation; this may add to the selectivity of sitespecific recruitment [111] .
The chemokines that are retained in the endothelial glycocalyx may come from two distinct sources. First, the endothelium itself has the capacity to secrete a range of chemokines on activation, including IL-8 and MCP-1. Alternatively, inflammatory cells, such as monocytes and fibroblasts beneath the endothelium, secrete chemokines that are subsequently transported to and retained in the endothelial glycocalyx. Another pro-adhesive factor, PAF, is also present at the vessel wall although the mechanism of its retention there is different. PAF is a phospholipid which is produced by endothelial cells within minutes of activation by thrombin, histamine or leukotriene. It is expressed at the endothelial surface but not released into the fluid phase. This endothelial-associated PAF can trigger neutrophil ␤2-integrin activation and promote transendothelial migration.
Strong, secondary adhesion is mediated by leucocyte integrins that bind members of the immunoglobulin superfamily on endothelium
Integrins are a family of heterodimeric membrane glycoproteins that can be grouped into families based on their ␤ subunit [7, 96] . The most important integrins for leucocytes are the ␤1-and ␤2-integrins. The ␤1-integrins include VLA-4 which is expressed on lymphocytes and monocytes, but not neutrophils. VLA-4 consists of a common ␤-chain (CD29) paired with the ␣-chain CD49d. It binds to the endothelial receptor VCAM-1 (CD102). VCAM-1 is absent from most non-inflamed endothelium but is expressed in response to pro-inflammatory cytokines and IL-4. The ␤2-integrins consist of LFA-1 (␤-chain CD18 paired with ␣-chain CD11a), MAC-1 (CD11b/Cd18) and gp150,95 (CD11c/CD18). LFA-1 is the dominant ␤2-integrin on lymphocytes but is also expressed on other leucocytes. It binds to two members of the intercellular adhesion molecule (ICAM) family of adhesion molecules, that are expressed on endothelium; ICAM-2 (CD) is constitutively expressed and mediates binding to resting endothelium, whereas ICAM-1 (CD54) expression is increased with activation and predominates in binding to inflamed endothelium [97] . MAC-1 (CD11b/CD18) is the dominant integrin on neutrophils and monocytes. It binds to ICAM-1 on activated endothelium. GP150,95 does not bind directly to endothelium although it can interact with endothelium via its ability to bind fibrinogen [71] .
The expression of integrin ligands by activated endothelium at sites of inflammation in vivo depends Table 5 Combination of molecular interactions mediate leucocyte subset recruitment. Each leucocyte can select one of several options at each step in the adhesion cascade. The individual interactions will not necessarily confer selectivity on recruitment but the combination of sequential interactions does. Examples are given for combinations that will result in the selection of distinct leucocyte subsets (for more details see ref. [97] )
Neutrophil
Monocyte Naive T-cell Skin memory T-cell
upon the nature of the endothelial-activating stimulus. For instance, both ICAM-1 and VCAM-1 can be induced on resting endothelium by exposure to the pro-inflammatory cytokines tumour necrosis factor ␣ (TNF␣), IL-1 and gamma interferon (␥IFN) whereas IL-4 selectively induces VCAM-1 expression [84, 91] . Furthermore, there are differences in the adhesion molecules expressed by endothelial cells from different tissues and in their responses to pro-inflammatory cytokines.
Migration
After binding strongly to endothelium the leucocyte migrates between the endothelial cells into tissue in a process called transendothelial migration or diapedesis. As mentioned above, many of the cytokines that trigger strong adhesion can also act as chemotactic factors to promote transendothelial migration [4, 100, 103] . Thus IL-8 induces chemotaxis of neutrophils as well as triggering their adhesion and MIP-1␤ can induce both adhesion and migration of T-lymphocyte subsets. As discussed below migration is dependent on regulated adhesion and deadhesion as well as on cytoskeletal rearrangement within the cell and it is not therefore surprising that these properties are frequently shared.
COMBINED EFFECTS OF SEQUENTIAL INTERACTIONS DETERMINE LEUCOCYTE SUBSET RECRUITMENT
The adhesion cascade provides a powerful model for controlling the specificity of leucocyte subset adhesion to endothelium that can be both rapidly amplified and carefully controlled. Specificity and regulation can be introduced at each of the sequential interactions giving rise to the paradigm proposed by Butcher and Springer of "area codes" for leucocytes [24, 97] . Thus, a particular leucocyte will have several options at each step of the cascade and it is the combined effects of the interactions that will determine the specificity of recruitment.
Regulation of leucocyte adhesion-physiological control vs pathological disorder
MULTI-STEP ADHESION IS A CONTROL STRATEGY THAT MAY BE SUBVERTED
Circulatory and molecular considerations outlined above suggest that selectin-mediated rolling adhesion is a prerequisite for leucocyte immobilization because it allows pick-up of localized signal(s) and because, for neutrophils at least, immobilizing integrin-mediated attachment cannot operate rapidly enough to capture flowing cells. However, multistep adhesion is not an absolute necessity in the sense that lymphocytes can be immobilized by a single integrin-immunoglobulin interaction [11] and that parasitized red cells can be immobilized by endothelial receptors directly from flow [29] . This suggests that rolling is part of an evolved control strategy rather than a physical necessity, and that signalling is the limiting process in multi-step adhesion. With rolling itself dependent on an endothelial response to stimulus, and neutrophil stabilization dependent on pick-up of signal from the endothelium after initial attachment, several controllable responses must occur in order to complete immobilization. Even then, further regulated steps must underlie onward neutrophil locomotion (which requires continual modulation of adhesive interaction to allow detachment at the rear of the cell and new attachment at the front), and migration in a preferred direction. The concept that neutrophils can move along a concentration gradient of chemoattractant is well established [27] , and one can foresee the existence of such a gradient in connective tissue containing an inflammatory stimulus. However, it is not clear how a gradient could be established in the presence of flowing blood, and so it seems that the neutrophils move across the surface and between endothelial cells along some other guideline. Taken together, migration requires a sequence of events and transformations, open to control at each stage and dependent on incompletely understood signalling responses. It is not surprising that multiple regulatory steps exist because, for instance, if neutrophil adhesion and migration were to proceed without tight control, then the potential for amplification of a catastrophic inflammatory reaction would be great. This raises the question as to whether pathological events follow a similar pattern and rely on the "normal" control sequence or whether various of the regulated steps are missing or out of order, bringing about uncontrolled and potentially damaging leucocyte-endothelial interaction.
KINETICS OF TRANSFORMATIONS IN THE MULTI-STEP SEQUENCE MAY BE CRITICAL FACTORS IN ITS
OUTCOME
If the multi-step process represents a strategy for controlling adhesion and migration, then the rate at which transformation between steps occurs will have a critical influence on the outcome. As noted above, capture of flowing blood cells requires a fast-acting adhesive interaction, but the kinetics of transformation to stable attachment may also be important. Several studies now show that initial tethering events may be short-lived and leucocytes may only make brief initial contact with endothelium, especially if receptors such as selectins are expressed at low level [10, 16] . This may be an advantage, in that if signals are not present, the tethered leucocytes will be swept away. It does imply, however, that signalling and leucocyte responses must be rapid for immobilization to be achieved. Indeed, recent studies show that short-lived interactions can underlie successful, signal-dependent immobilization of lymphocytes in lymph nodes [16] , and our own observations indicate that neutrophils can respond to adhesion-promoting, activating stimuli in seconds and probably even more rapidly [76, 90] . When rolling adhesion is more long-lived, there may not appear to be a necessity for such rapid signalling, but if leucocytes are to be localized accurately, then they must still come to a halt within a short distance of exposure to stimulus.
Clearly this can only be achieved by localizing the stimulus, i.e. as noted above, on the cell surface rather than relying on the fluid phase. Moreover, failure to localize the stimulus or the cell response would lead to undesirable dispersal of active cells or mediators into the systemic circulation.
After immobilization of leucocytes on the endothelial surface, transformation to migration might be able to occur at a more leisurely pace. However, its successful completion is necessary because otherwise the vessel lumen is in danger of occlusion, and because the immobilized neutrophil contains an arsenal of lytic enzymes, has great oxidant potential and is capable of producing mediators which could attract further leucocytes to the site. In fact, it is unclear how activated neutrophils order such events. In vitro stimuli tend to induce oxidative bursts, degranulation and release of mediators along with pro-adhesive changes. In vivo, adhesion must come first, followed by migration, and then the destructive potential needs to be unleashed on contact with foreign bodies or necrotic tissue. Thus, there must be a lag of the order of minutes and a dissociation of the responses that is not always evident in vitro. We have seen very high levels of neutrophil attachment and migration on cytokine-stimulated endothelial cells without apparent damage to the monolayer (unpublished observations), so that some form of "pathological" priming such as hypoxia may be required to induce neutrophils to cause endothelial damage [43] . Control and localization of the neutrophil lytic response might come about through some endothelial regulatory factor (such as nitric oxide) and it may be that stimulation protocols used for neutrophils in suspension in vitro do not mimic the situation when initial stimuli are presented on the endothelial surface.
Adhesive leucocytes must thus clear the vessel lumen before proceeding to other functional responses. Otherwise obstruction in the lumen could be amplified by neutrophil-neutrophil interaction, such as homotypic aggregation and transfer of activating agents such as PAF and Il-8. At high levels of neutrophil adhesion in in vitro flow models we have found evidence of activated adherent cells forming contacts and building quite large aggregates if they cannot transmigrate [G. E. Rainger, G. B. Nash, unpublished observations]. Thus, uncontrolled adhesion could lead to impaired perfusion and intravascular damage if neutrophils do not migrate, as well as destruction of surrounding tissue if they do.
DO PATHOLOGICAL EVENTS FOLLOW THE PHYSIOLOGICAL SEQUENCE?
The foregoing suggests two main possibilities: that pathological adhesive interactions follow a normal controlled sequence, but that they occur at an inappropriate or undesired time or over a prolonged period; that disordered or unregulated processes lead to uncontrolled build up of leucocytes and tissue damage, for example if activation occurs before immobilization or cells fail to complete the full response. In fact, both scenarios are likely in vivo.
Although rolling, signalling, stopping and migration may occur in sequence (perhaps after hypoxia and reoxygenation judging from in vitro studies [75] ), steps might be missed out under special circumstances. The necessity for selectin-mediated adhesion might be lost, for example, under low-flow conditions where activated integrins would be able to immobilize neutrophils directly [70] , or in tissues with unusual architecture or flow pattern, such as the lungs. Moreover, the initial step might be mechanical rather than adhesive. Impaired neutrophil deformability is associated with number of ischaemic disorders [62, 64, 65] , smoking [89] and circulating antineutrophil cytoplasm antibodies associated with autoimmune vasculitis [25] . Loss of deformability has been shown to be capable of causing trapping of neutrophils in the lungs independent of adhesion [112] , and so adhesive and damaging interactions could follow on from mechanical changes without initial endothelial exposure of tethering molecules. Moreover, it may not be correct to treat mechanical and adhesive responses as separate, because the time courses of each are similar (rapid initial phase in seconds, followed by modulation over minutes), and there is evidence that skeletal structures within the cell regulate adhesive behaviour [46] .
The concept of out-of-order adhesion is not so well documented, although it is known that if eosinophil integrins are "frozen" in an activated state the cells can no longer migrate [50] . Successful neutrophil immobilization seems to rely on activation of constitutive integrins while migration requires integrin deactivation and successive waves of new integrin expression and activation [41, 90] . Disruption of this sequence might interfere with its continuation. Activated neutrophils bind to resting endothelial cells but show little migration compared with neutrophils bound to cytokine-treated endothelium (unpublished observations), so that activation of only one side of the leucocyte-endothelial interaction results in an incomplete response. As noted above, the phagocytic and lytic responses of leucocytes need to occur at the right time, and there is the hypothetical possibility at least that pathology can arise if they are induced before migration. Compared with the current quite extensive knowledge of adhesion molecules themselves, the regulation of transformations (rolling to stopping; stopping to migration; migration to phagocytosis/degranulation) is an outstanding puzzle, and its manipulation may be a route to achieving control of inflammation.
DO OTHER CELL-CELL INTERACTIONS INCREASE THE PATHOLOGICAL POTENTIAL OF ADHESION BETWEEN LEUCOCYTES AND ENDOTHELIUM?
Adhesion of leucocytes to endothelium may be the primary promoter of vascular pathology, but there are other forms of intercellular interaction with "physiological" or "pathological" potential that are worthy of comment ( fig. 5 ). As noted previously, monocyte/macrophages provide cytokines and chemokines which can activate endothelium, neutrophils and lymphocytes. Less well recognized is the likelihood that platelets modulate the inflammatory response. Platelet attachment to sub-endothelial matrix is an essential part of haemostasis. However, they can also bind to leucocytes in blood and can act as an adhesive surface for flowing leucocytes [26, 78] , interactions of uncertain physiological function. Immobilized platelets support both rolling attachment of unstimulated neutrophils and stationary attachment of activated cells [26, 90] . In addition, platelets and neutrophils are capable of releasing factors which activate each other and the response of each to stimulus is greater in the presence of the other, for example because of their capability to exchange metabolites of arachidonic acid (eicosanoids) and because of release of neutrophil granule enzymes (see ref. [63] for review). Thus, one may predict that co-localization of platelets and neutrophils would amplify the inflammatory response, and evidence from animal models suggest that reperfusion injury and thrombosis in vessel grafts are indeed augmented by their interaction [58, 68] . It may also be worth noting that biochemical interactions may be three-cornered, including the endothelial cells which release factors modulating platelet response (e.g. prostacyclin and nitric oxide) but can also participate in exchange of metabolites of arachidonic acid with platelets and neutrophils [56] .
Interaction between leucocytes may also occur within the lumen. Homotypic aggregation between neutrophils occurs after stimulation in purified suspensions and in blood, and is associated with agents such as activated components of complement (e.g. generated during haemodialysis) [30, 49] . The mechanism of aggregation appears to involve both integrin-and selectin-mediated adhesion [94] . If an immobilized neutrophil acts as a focus for attachment of others flowing past, then the potential for vascular occlusion is great; alternatively, aggregates formed in the blood would block small vessels directly. The circulatory conditions under which such interactions occur and the molecular mechanisms appear worthy of further attention.
Leucocyte-endothelial interactions and disease
Leucocyte-endothelial interactions are vital for effective host defence against pathogens and when they fail overwhelming sepsis can result. This is best illustrated by two rare inherited disordersleucocyte adhesion deficiency type 1 (LAD-1) and type 2 (LAD-2) that are associated with deficiency of CD18 and sialyl Lewis X respectively. Both syndromes result in dramatically reduced neutrophil recruitment to sites of inflammation and are associated with recurrent life-threatening sepsis. In addition to their role in protecting the host, leucocyte-endothelial interactions can contribute to the generation of unwanted, pathological inflammation in such conditions as reperfusion injury after ischaemia, septic shock, autoimmunity, allergic responses and allograft rejection. For example, pulmonary infiltration as part of the adult respiratory distress syndrome (ARDS) is a serious complication of septic shock resulting from acute pancreatitis. Although the original focus of disease is distant from the lung, neutrophils are inappropriately recruited to the pulmonary bed because of enhanced adhesion to the pulmonary microvasculature. The increased adhesion of leucocytes to microvasculature in the liver, lung and kidney is a crucial factor in the development of MOF in septic shock and, as discussed above, results from increased rigidity and inappropriate activation of adhesion molecules on circulating leucocytes [37] or from activation of the endothelium by circulating factors such as endotoxin or LPS [23] . The role of leucocyte adhesion to endothelium in this setting is demonstrated by the fact that the development of ARDS can be inhibited by the administration of antibodies to block CD18 or the use of oligosaccharides that block leucocyte binding to selectins [59] . In addition, mice that are genetically deficient in ICAM-1 are resistant to the fatal complications of septic shock [22] .
Increased expression of endothelial adhesion molecules is associated with a range of inflammatory disorders from graft rejection to liver cirrhosis [21] . Acute inflammatory disorders are associated with infiltration by neutrophils and tend to be accompanied by increased expression of E-selectin and P-selectin whereas in chronic, lymphocytic inflammation ICAM-1 and VCAM-1 expression predominate. Thus, E-selectin is strongly expressed on endothelium in acute appendicitis and is found in high concentrations in the circulation in septic shock, whereas VCAM-1 is induced during the chronic inflammation of sarcoidosis and graft rejection, conditions associated with a lymphocytic infiltrate [66] . However, these distinctions are often less clearcut and E-selectin, ICAM-1 and VCAM-1 may be expressed together at sites of chronic inflammation. However, caution should be used when interpreting studies based on increased expression of adhesion molecules [74] . The presence of a particular adhesion molecule does not always imply it has a functional role in that particular clinical setting. For example, E-selectin is upregulated on endothelium in the chronic immune-mediated liver disease, primary biliary cirrhosis, suggesting it is important for the generation of the chronic inflammatory infiltrate. However, very few of the infiltrating leucocytes in this disease express receptors capable of binding Eselectin suggesting that E-selectin expression in this disease is a consequence of the local inflammation and of no direct relevance to leucocyte recruitment [8] .
There are now accumulating data on chemokine expression in a number of inflammatory diseases. Transplant graft rejection is associated with increased tissue expression of RANTES, ENA-78, MIP-1␣ and MIP-1␤ [2, 69, 86] and a wide range of other immune-mediated diseases have been associated with increased chemokine expression and secretion [19, 40, 77, 87, 95] . The ability of IL-8 to trigger neutrophil recruitment suggests it will be involved in the inflammatory response of sepsis and several studies have shown increased circulating IL-8 in patients with septic shock [57] . In addition, anti-IL-8 treatment can ameliorate some of the features of sepsis in animal models. It has recently been suggested that MIP-1␣ also plays a crucial role in septic shock and it is likely that a network of chemokines will be involved in this complex disease [55, 98] .
Thus, in order to understand the pathogenesis of an inflammatory response one requires a detailed understanding of the dynamic regulation of all elements in the adhesion cascade.
SOLUBLE ADHESION MOLECULES IN INFLAMMATION
Many cell surface adhesion molecules are shed into the fluid phase in response to cellular activation [66, 80] . These include the leucocyte adhesion molecules L-selectin and CD31 and the endothelial adhesion molecules ICAM-1, VCAM-1 and the selectins. The functions of soluble adhesion molecule release are not known. There is evidence that soluble E-selectin can activate neutrophils suggesting it might act as an inflammatory mediator [53] . Alternatively other groups have suggested that soluble adhesion molecules are a homeostatic mechanism to block adhesion and downregulate inflammatory responses [35] . Whatever their functional significance soluble CAMs are markers of inflammation in a range of acute and chronic inflammatory disorders [3, 5, 35] . However, few studies have shown any great prognostic or diagnostic advantage in measuring adhesion molecules compared with other markers of inflammation.
THERAPEUTIC IMPLICATIONS
The recent advances made in understanding the molecular basis of leucocyte-endothelial interactions suggest new approaches for therapeutic intervention in a range of inflammatory diseases [1] . Monoclonal antibodies that block the function of particular adhesion molecules have been used to prevent tissue infiltration by leucocytes in animal models. For example, antibodies to E-selectin prevent antigeninduced airway hyper-responsiveness in a primate model of asthma by inhibiting neutrophil infiltration and in models of reperfusion injury antibodies to ICAM-1 and CD18 have successfully reduced tissue infiltration and damage caused by neutrophils [18, 36, 47, 110] . In addition to therapy aimed at blocking acute inflammation other studies have addressed the treatment of chronic immune disorders. Antibodies to VLA-4 reduce T-cell infiltration into the brain and slow disease progression in a rat model of multiple sclerosis suggesting that anti-adhesion molecule therapy might prove beneficial in autoimmune diseases [17, 113] .
Clinical trials of anti-adhesion molecule therapy are few; antibodies to ICAM-1 have shown only limited promise in the treatment of graft rejection and rheumatoid arthritis and the use of murine monoclonal antibodies to treat chronic autoimmune diseases is complicated by the development of neutralizing anti-murine antibodies [32, 39] . The development of humanized or chimeric antibodies overcomes the latter problem but other treatments based on molecular analogues have many pharmacological advantages. Such therapy has recently been tested in animals. Peptides that bind to and block the function of the leucocyte integrin Mac-1 (CD11b) have been used to reduce neutrophil infiltration and tissue damage in bacterial meningitis [105] . Infusions of oligosaccharides containing sialyl-Lewis X, the carbohydrate ligand for Pselectin and E-selectin, prevented neutrophilmediated lung injury induced by injections of cobra venom, a model with many features that are similar to ARDS [60] .
More recently, therapy aimed at blocking chemokines has been tested in animal models of inflammation. Anti-MCP-1 treatment prevents the development of granulomatous lung disease in a murine model [54] and anti-IL-8 treatment reduces reperfusion lung injury [88] .
It is likely that the next few years will see the development of new therapies to prevent leucocyteendothelial interactions by directly inhibiting the adhesion molecules involved or by modulating their regulation by inhibiting cytokine-induced signalling in endothelium or blocking the actions of the chemokines that trigger leucocyte adhesion molecules. However, the complexity of the processes involved suggests that simple approaches to therapy are unlikely to be successful and that blocking a particular molecule may have consequences that were initially unforeseen. It is thus essential that such studies are investigated and set up in the context of the adhesion cascade and tested thoroughly before being applied to clinical disorders such as septic shock.
